- Home
- PSFE vs REPL Comparison
PSFE vs REPL Comparison
Compare PSFE & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- REPL
- Stock Information
- Founded
- PSFE 1996
- REPL 2015
- Country
- PSFE United Kingdom
- REPL United States
- Employees
- PSFE N/A
- REPL N/A
- Industry
- PSFE Business Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PSFE Consumer Discretionary
- REPL Health Care
- Exchange
- PSFE Nasdaq
- REPL Nasdaq
- Market Cap
- PSFE 856.2M
- REPL 753.9M
- IPO Year
- PSFE N/A
- REPL 2018
- Fundamental
- Price
- PSFE $11.86
- REPL $9.27
- Analyst Decision
- PSFE Sell
- REPL Strong Buy
- Analyst Count
- PSFE 4
- REPL 7
- Target Price
- PSFE $17.38
- REPL $20.83
- AVG Volume (30 Days)
- PSFE 461.6K
- REPL 1.3M
- Earning Date
- PSFE 08-12-2025
- REPL 08-07-2025
- Dividend Yield
- PSFE N/A
- REPL N/A
- EPS Growth
- PSFE N/A
- REPL N/A
- EPS
- PSFE N/A
- REPL N/A
- Revenue
- PSFE $1,688,097,000.00
- REPL N/A
- Revenue This Year
- PSFE $2.88
- REPL N/A
- Revenue Next Year
- PSFE $6.73
- REPL N/A
- P/E Ratio
- PSFE N/A
- REPL N/A
- Revenue Growth
- PSFE 3.50
- REPL N/A
- 52 Week Low
- PSFE $11.60
- REPL $6.44
- 52 Week High
- PSFE $26.25
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- PSFE 37.24
- REPL 49.26
- Support Level
- PSFE $12.06
- REPL $9.50
- Resistance Level
- PSFE $12.54
- REPL $10.09
- Average True Range (ATR)
- PSFE 0.39
- REPL 0.60
- MACD
- PSFE 0.03
- REPL -0.06
- Stochastic Oscillator
- PSFE 2.09
- REPL 9.76
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.